Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 23, 2020

View Archived Issues

Grant supports Epsilogen's development of cancer immunotherapeutic EPS-201

Targeting periphery could be viable approach in ALS

Ideaya and the Broad Institute partner to advance synthetic lethality programs

GlaxoSmithKline patents hSTING agonists

Kowa discloses CSF-1R inhibitors

TaiwanJ Pharmaceuticals presents new ENPP2 and HDAC dual inhibitors

Tera Stone synthesizes new compounds for cancer

Researchers discover new CNKs as antitumoral agents

FDA clears IND application for first-in-human study of ADI-001

Ionis initiates phase I/II study of ION-541 to treat broad ALS population

First-in-human data presented for JAK3 inhibitor TD-5202

Lp-PLA2 inhibition may limit cardiovascular damage from radiotherapy

FDA approves Veklury for patients with COVID-19 requiring hospitalization

Galera initiates phase I/II GRECO-1 study of GC-4711 plus SBRT in NSCLC

FDA issues complete response letter for Qtrypta

Preclinical data presented on intranasal oxytocin formulation for IBS

SGX-301 continues to demonstrate positive benefits in phase III FLASH study

ProTrans approved for clinical trials in patients with COVID-19

New phase II trial investigates PT-112 for metastatic CRPC

SARS-CoV-2 vaccine BBIBP-CorV safe and induces humoral responses in phase I/II study

bit.bio and London Institute for Mathematical Sciences partner on production of human cells

Adalimumab s.c. efficacious and safe option for children with ulcerative colitis

Altered cathepsin K secretion contributes to congenital heart defects in a model of mucolipidosis II

Phase III studies of a quadrivalent virus-like particle influenza vaccine manufactured in plants

AstraZeneca initiates phase III trial of monalizumab in recurrent or metastatic SCCHN

Tetra reports findings with ARDS-003 in induced pulmonary fibrosis model

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...